GeoVax Publishes Dual-Antigen COVID-19 Vaccine Showing Durable Phase 2 Responses
Early Phase 2 readouts show GeoVax’s GEO-CM04S1 vaccine elicited durable antibody and T-cell responses in hematologic malignancy transplant recipients and chronic lymphocytic leukemia patients with impaired immunity. The MVA-vectored, dual-antigen design (spike plus nucleocapsid) targets conserved viral proteins to enhance breadth and durability of protection in immunocompromised populations.
1. Publication Details
GeoVax announced publication of a peer-reviewed article in a European medical journal outlining the scientific rationale, preclinical data and clinical findings for GEO-CM04S1, its next-generation COVID-19 vaccine designed specifically for immunocompromised individuals.
2. Phase 2 Trial Readouts
Early data from ongoing Phase 2 trials in hematologic malignancy transplant recipients and chronic lymphocytic leukemia patients show GEO-CM04S1 generates durable humoral and cellular immunity despite impaired baseline immune function.
3. Development Outlook
GEO-CM04S1 is currently enrolled in multiple Phase 2 studies as both primary and booster vaccination in immunocompromised cohorts, with plans to advance clinical development based on safety and immunogenicity outcomes.